OBJECTIVE:Secondary Restless Legs Syndrome (RLS) has repeatedly been associated with psychopharmacotherapy, especially antidepressants and antipsychotics. However, existing evidence is conflicting in terms of the magnitude of the association as well as the significance of substance classes or individual compounds. The objective of the present study was to evaluate secondary RLS linked to psychotropic medication in real-world, inpatient clinical routine treatment settings. METHODS:A large dataset from a multinational pharmacovigilance program in German-speaking countries (Arzneimittelsicherheit in der Psychiatrie, "Drug safety in Psychiatry") from January 2001 to December 2016 was retrospectively analyzed. RESULTS:In a total of 340 099 monitored inpatients, 67 cases of newly diagnosed and severe RLS related to psychotropic drug treatment were recorded equivalent to a relative frequency of 0.02%. Over 80% of the cases were attributable to two compounds: the antidepressant mirtazapine and the antipsychotic quetiapine. Mirtazapine was found in 39 patients, while quetiapine was found in 16 patients with secondary RLS. For both substances, drug dosages were generally low at onset of secondary RLS. Most cases exhibited an onset within 1 or 2 days after dosage start or change. CONCLUSION:Histamine neurotransmission may represent a crucial common denominator in terms of secondary RLS in association with psychopharmacotherapeutics, as both substances exhibit antihistamingeric effects at lower dosages.
Background: We assessed the association between different adverse drug reactions (ADRs) and patients with versus without lithium co-medication using data from the European drug surveillance program AMSP (German: “Arzneimittelsicherheit in der Psychiatrie,” i.e. Drug Safety in Psychiatry) Methods: We conducted a case/non-case pharmacovigilance study using AMSP data on ADRs from patients treated in psychiatric hospitals in Germany, Austria, and Switzerland. We performed a disproportionality analysis of reports of severe ADRs from patients with versus without lithium co-medication calculating reporting odds ratios (RORs). Additional analyses included comparisons with distinct pharmacological classes, reports where the imputation grade for ADRs was probable or certain, and where ADR rates were related to exposed patients. Results: In 8609 patients, lithium-treated patients ( n = 720) were less often associated with weight gain, dyskinesia, suicidality (as an ADR), hyponatremia, and mortality, but more often associated with various types of neurotoxicity ( p < 0.05 in all cases). Parkinson’s symptoms (ROR 1.8), tremor (ROR 4.6), serotonergic ADRs (ROR 3.0), ataxia or myoclonus (each, ROR 2.7), as well as drug-drug interactions leading to intoxication (ROR 26.3, p < 0.05 in all cases). When stratifying by pharmacological class, hyponatremia was more frequent in patients receiving different pharmacological classes ( p < 0.05 in all cases), whereas neurotoxicity and lithium intoxications were more frequently reported in lithium comedication groups ( p < 0.05 in all cases). Conclusions: Patients treated with lithium are associated with a reduced reporting of hyponatremia, but to an increased reporting of neurotoxicity, although findings represent reporting associations, rather than incidence estimates or causal effects.
Purpose This study investigated the effects of age and sex on swimming performance in master breaststroke swimmers competing in the World Aquatics Master Championships. Methods For all Master World Championships held between 1986 and 2024, the year of competition, first name, last name, age, age group, stroke and distance were recorded for each swimmer. Descriptive data were presented using mean, standard deviation, and maximum and minimum values. Generalised linear models (GLMs) with a gamma probability distribution and a log-link function assessed the effect of age group and sex on swimming time. Results Between 1986 and 2024, most swimmers (40.7%) competed in the 50 m event (n = 17,575; 7,911 women and 9,664 men), followed by the 100 m event (35.2%, n = 15,211; 7,158 women and 8,053 men), and the 200 m event (24.0%, n = 10,373; 4,934 women and 5,439 men). The GLM results indicated that sex, age group, and the interaction between sex and age group all had significant effects on the 50, 100, and 200 m races. For 50 m races, the effect of sex was significant ( χ2 (1) = 2662.669, p < 0.001), as was the effect of age group ( χ2 (13) = 16407.620, p < 0.001), and the interaction between sex and age group ( χ2 (13) = 233.234, p < 0.001). Conclusions The study revealed that men were generally faster than women in all distances and age groups, except for the 90+ age group in the 100 and 200 m events. Future studies could investigate other strokes and distances. Coaches and sports scientists could use these findings to improve the preparation of their master athletes.
Die Studie untersucht im Rahmen des flexiblen, suizidspezifischen Attempted Suicide Short Intervention Program (ASSIP flex) Veränderungen in der therapeutischen Allianz und der Selbstwirksamkeit. Zudem wird der Zusammenhang zwischen der Selbstwirksamkeit und dem suizidalen Erleben analysiert. Die Studie ist als Subanalyse einer längsschnittlichen Beobachtungsstudie konzipiert. Die Stichprobe umfasste 64 Patient/-innen (51,6% Frauen) im Alter von 19–83 Jahren (M=39,6, MD=35,5, SD=15,7) mit suizidalem Verhalten, die an ASSIP flex teilnahmen. Die Befragung erfolgte zu zwei Messzeitpunkten, vor (t0) und nach (t1) der ASSIP flex-Behandlung sowie im Anschluss an jede der drei ASSIP flex-Sitzungen. Zu den beiden Messzeitpunkten wurden soziodemografische Merkmale (z. B. Geschlecht, Alter), gesundheitsbezogene Daten (z. B. therapeutische Allianz, Selbstwirksamkeit) sowie Angaben zum suizidalen Erleben und Verhalten (z. B. Intensität der Suizidgedanken, Anzahl Suizidversuche) erhoben. Die therapeutische Allianz wurde nach jeder ASSIP flex-Sitzung erfasst. Im Verlauf der drei Therapiesitzungen wurde eine Zunahme der therapeutischen Allianz festgestellt (F(1, 63)=48,081, p<0,001). Von t0 zu t1 wurde eine Erhöhung der Selbstwirksamkeit beobachtet (t(63)=−3,410, p<0,001). Ein positiver Zusammenhang zwischen der Selbstwirksamkeit zu t0 und der therapeutischen Allianz wurde sowohl in der ersten (β=0,433, p<0,001) als auch in der dritten Therapiesitzung (β=0,293, p=0,041) festgestellt. Das suizidale Erleben der Patient/-innen verringerte sich von t0 zu t1 (BSS: β=−0,220, p<0,001). Eine höhere Selbstwirksamkeit war mit geringerem suizidalem Erleben assoziiert (BSS: β=−0,315, p<0,001). Die Ergebnisse unterstreichen die Relevanz der therapeutischen Allianz und der Selbstwirksamkeit in der suizidpräventiven Behandlung. Der narrative Ansatz von ASSIP flex bietet dabei eine strukturierte Möglichkeit, um sowohl die therapeutische Allianz als auch die Selbstwirksamkeit gezielt zu stärken. In Follow-up Studien sollten die Zusammenhänge dieser Konstrukte mit dem suizidalen Erleben und Verhalten über einen längeren Zeitraum untersucht und gezielte Interventionsstrategien weiterentwickelt werden.
This project aimed at (1) detailing the complex side effect patterns of 902 inpatients treated for major depression or schizophrenia under polypharmacy regimens; (2) developing a quantitative side effect model that accounts for the various facets of clinically observable adverse events; and (3) analyzing irregularities in genetic diversity through multidimensional “gene vectors” in order to reveal possible interrelations with side effect clusters. The patients’ acute medication, their time course of recovery, and their side effects were assessed by up to 8 repeated measurements. The genotyping included 100 candidate genes with genotypic patterns computed from 549 Single Nucleotide Polymorphisms (SNPs). Between 61.9